0001437749-20-012741.txt : 20200609
0001437749-20-012741.hdr.sgml : 20200609
20200609163854
ACCESSION NUMBER: 0001437749-20-012741
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200608
FILED AS OF DATE: 20200609
DATE AS OF CHANGE: 20200609
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tucker Sean
CENTRAL INDEX KEY: 0001652204
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35285
FILM NUMBER: 20952372
MAIL ADDRESS:
STREET 1: 385 OYSTER POINT BLVD., SUITE 9A
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vaxart, Inc.
CENTRAL INDEX KEY: 0000072444
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 591212264
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 385 OYSTER POINT BOULEVARD, SUITE 9A
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 550-3500
MAIL ADDRESS:
STREET 1: 385 OYSTER POINT BOULEVARD, SUITE 9A
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: Aviragen Therapeutics, Inc.
DATE OF NAME CHANGE: 20160413
FORMER COMPANY:
FORMER CONFORMED NAME: Biota Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20121113
FORMER COMPANY:
FORMER CONFORMED NAME: NABI BIOPHARMACEUTICALS
DATE OF NAME CHANGE: 20100719
4
1
rdgdoc.xml
FORM 4 TUCKER
X0306
4
2020-06-08
0000072444
Vaxart, Inc.
VXRT
0001652204
Tucker Sean
C/O VAXART, INC.
385 OYSTER POINT BOULEVARD, SUITE 9A
SOUTH SAN FRANCISCO
CA
94080
1
Chief Scientific Officer
Stock Option (right to buy)
1.70
2020-06-08
4
A
0
360000
0
A
2030-03-23
Common Stock
360000
360000
D
The option grant was approved by the board of directors of Vaxart, Inc. on March 24, 2020, subject to stockholder approval of an amendment to the Vaxart, Inc. 2019 Equity Incentive Plan, under which the stock option was granted. Vaxart, Inc.'s stockholders approved the plan amendment on June 8, 2020.
The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on the date of grant, and thereafter in 24 equal monthly installments commencing on the first day of the calendar month following the grant date such that the stock option shall be fully vested on April 1, 2022.
/s/ Sean Tucker
2020-06-09